White Papers
The ‘antibiotic crisis’ is rarely out of the news these days, with headlines issuing dire warnings that the rise in resistance to anti-microbial drugs could result in a return to the medical dark ages. In order to tackle this problem, various initiatives have been proposed on both sides of the Atlantic, both to incentivise research into novel antibiotics and to change current prescribing behaviour in an attempt to limit the spread of resistance to existing antibiotic drugs.
White Papers
The ophthalmology device segment has experienced robust transaction activity with over 500 transactions taking place between January 2010 and the end of the first quarter in 2015.
In this white paper we look at the range of transaction activity by type, geography and stage, take a look at the sector market performance so far and discuss what we can expect in the future.
White Papers
Leading CMOs are developing acquisition strategies based on reinforcing their customer base, expanding their geographic reach and broadening their capabilities. Similarly, customers are increasingly demanding simpler sourcing models that can deliver speed and reliability.
Divestment is often the most favoured strategy for surplus manufacturing or R&D assets. Our experience has taught us that delays in the divestment process can significantly erode value and diminish attractiveness to buyers. Speed and control of the selling process are in a seller’s best interest as site operating costs usually make up a significant part of business operations. Every month of delay could add unnecessary thousands, if not millions to operating costs prior to a sale.
White Papers
Immuno-oncology is the latest and perhaps the most exciting development in cancer and immunotherapy. In this white paper we take a look at the history and the recent deal activity and at why we can expect this to be a hot area for deal making in the immediate future.
White Papers
Deal-making is one of the key strategies employed by pharma companies to fuel growth opportunities. On a spectrum that ranges from intramural organic growth to extramural outright acquisitions, pharma deal-making occupies an intermediate position. One can easily argue that analogous to semi-active investment, this approach should yield highest return for the company as well as its investors on a risk-normalised basis.
Taking an integrated high-throughput approach allows the cross-sectional assessment of the deal-making activities of a group of companies over a certain period of time in an effi cient manner. In line with this framework, one can decompose the pharma deal-activity into various elements that integrates science at the bottom of the pyramid through to corporate strategy at the top of the pyramid. This integrated approached could be construed as an enterprise-wide deal activity scorecard.
White Papers
It is not surprising that mostly small to medium sized companies seek the help of specialist consultancies to find commercial partners or find in-licensing opportunities. Large pharma are in the attractive position that they get thousands of unsolicited licensing offers from small R&D companies every year and they have ample capacity to conduct due diligence on the promising candidates and partners. Their real concern is whether they can spot hidden gems from less commercially active research boutiques that do not actively search for partners early on before competition sees them. Additionally, large pharma regularly faces the issue of rejecting opportunities that their competition may pick up and in these situations the inevitable internal questions arise from senior executives about the effectiveness of the internal evaluation capabilities.
